CTOs on the Move

OXiGENE

www.oxigene.com

 
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.oxigene.com
  • 701 Gateway Blvd Suite 210
    South San Francisco, CA USA 94080
  • Phone: 650.635.7000

Executives

Name Title Contact Details

Similar Companies

Cameron Miller

Cameron Miller is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boehringer Wound Systems

Boehringer Wound Systems is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.

Lightforce Orthodontics

The World`s First, and Only, Fully-Customized 3D Printed Bracket System

pulmoguard healthcare

pulmoguard healthcare is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.